0001209191-20-058944.txt : 20201117
0001209191-20-058944.hdr.sgml : 20201117
20201117210011
ACCESSION NUMBER: 0001209191-20-058944
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201116
FILED AS OF DATE: 20201117
DATE AS OF CHANGE: 20201117
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: REED ELIZABETH E
CENTRAL INDEX KEY: 0001283303
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36257
FILM NUMBER: 201322712
MAIL ADDRESS:
STREET 1: 9050 CAMINO SANTA FE
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Travere Therapeutics, Inc.
CENTRAL INDEX KEY: 0001438533
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 262383102
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3611 VALLEY CENTRE DR
STREET 2: SUITE 300
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: 888-969-7879
MAIL ADDRESS:
STREET 1: 3611 VALLEY CENTRE DR
STREET 2: SUITE 300
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
FORMER COMPANY:
FORMER CONFORMED NAME: Retrophin, Inc.
DATE OF NAME CHANGE: 20130220
FORMER COMPANY:
FORMER CONFORMED NAME: Desert Gateway, Inc.
DATE OF NAME CHANGE: 20080625
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-11-16
0
0001438533
Travere Therapeutics, Inc.
RTRX
0001283303
REED ELIZABETH E
C/O TRAVERE THERAPEUTICS, INC.
3611 VALLEY CENTRE DR., SUITE 300
SAN DIEGO
CA
92130
0
1
0
0
SVP, GC & Corporate Secretary
Common Stock
2020-11-16
4
S
0
2500
23.98
D
25431
D
The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.74 to $24.32,
inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and
Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
/s/ Elizabeth E. Reed
2020-11-17